Trial Profile
A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Cougar Biotechnology
- 16 Feb 2011 Planned end date changed from 1 Mar 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 01 Jun 2009 Results were presented at the 2009 ASCO Annual Meeting, according to a Cougar media release.
- 01 Jun 2009 To date, a total of 58 patients have been enrolled in the trial at 8 different centers, according to a Cougar Biotech media release.